• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login

    • Heart Failure Drugs

    ID: MRFR/Pharma/7288-CR
    104 Pages
    Rahul Gotadki
    June 2020

    Heart failure is a medical condition characterized by the heart's inability to pump blood effectively, leading to a range of symptoms and complications. Various pharmaceutical companies are involved in the development and production of drugs used in the management and treatment of heart failure. These drugs aim to alleviate symptoms, improve cardiac function, and reduce the risk of adverse events.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Heart Failure Drugs Market Research Report - Forecast till 2032 Infographic
    Summary Table of Contents Segmentation Infographic

    Top Industry Leaders in the Heart Failure Drugs Market

    Heart Failure Drugs Key Companies*Disclaimer: List of key companies in no particular orderLatest Heart failure Companies Update

    May 2023: The U.S. Food and medicine Administration has greenlighted a medicine developed by Lexicon Pharmaceuticals Inc to treat heart failure in a wide range of patients, including adults with type 2 diabetes. Sotagliflozin, marketed under the trade name Inpefa, is the company's first FDA-approved oral medication. As an adjunct to insulin treatment for type 1 diabetes, it has previously been rejected for clearance in the United States. Inhibiting SGLT1 and SGLT2 proteins, which sotagliflozin does, helps manage blood glucose levels and reduces the risk of weight gain. The drug is scheduled to be released by Lexicon at the end of June, and the company has stated that the wholesale pricing will be comparable to other branded heart failure drugs.


    July 2023: The Drugs Controller General of India gave AstraZeneca Pharma India permission to import Dapagliflozin tablets for the treatment of heart failure in July 2023. According to a regulatory document, the pharmaceutical business has been granted approval by the DCGI to import pharmaceutical formulations of a new medicine for sale. It went on to say that dapagliflozin capsules and tablets should be used to treat adult heart failure. This approval clears the way for the product to be marketed in India for the designated use, pending the acquisition of any necessary government permits.


    Janaury 2023: Tablets with a combination of sacubitril and valsartan, intended for use in the treatment of heart disease, were released by Glenmark Pharmaceuticals in India in January 2023. Sacu V is a cutting-edge, cost-effective medication that has been found to relieve symptoms related to heart failure with reduced ejection fraction (HFrEF) and minimize the risk of cardiovascular mortality or hospitalization. According to the manufacturer, a doctor's prescription is required for both daily doses of Sacu V. Its FDA-approved use is for treating individuals with chronic heart failure and HFrEF to lessen the likelihood of cardiovascular-related deaths and hospitalizations.List of Heart failure Key companies in the market



    • Amgen Inc. (US)

    • AstraZeneca (UK)

    • Novartis AG (Switzerland)

    • Boehringer Ingelheim International GmbH (Germany)

    • Johnson & Johnson Services

    • Bristol-Myers Squibb Company (US)